Literature DB >> 7522041

Correlation of loss of heterozygosity at 11p with tumour progression and survival in non-small cell lung cancer.

K M Fong1, P V Zimmerman, P J Smith.   

Abstract

Loss of heterozygosity (LOH) affecting loci at 11p13 and 11p15 occurs in childhood and adult carcinomas, including non-small cell lung cancer (NSCLC). In NSCLC, the highest reported frequency of LOH was 72% at the 11p13 catalase (CAT) locus. As this locus is centromeric to the Wilms' tumour (WT1) locus, possible involvement of WT1 in the pathogenesis of NSCLC was considered. We thus examined 101 cases of NSCLC for LOH at the WT1 and five other polymorphic loci along 11p. At 11p13, the frequencies of LOH were 20% (9/46) at the FSHB locus, 9% (5/53) at the WT1 locus, and 15% (6/41) at the CAT locus. The shortest region of overlap (SRO) at 11p13 was mapped centromeric to, but excluding, the WT1 locus. Only adenocarcinomas showed LOH in this region. At 11p15, LOH affected 23% (18/77) of informative cases, with the highest frequency of 36% at the insulin (INS) locus. The SRO at 11p15 was mapped telomeric to the RRM1 locus. A third region, at 11p13-15 between WT1 and RRM1, was also affected by LOH. LOH at 11p correlated significantly with advanced T stage and nodal involvement in NSCLC tumours. In the squamous cell carcinoma subtype, LOH along 11p also correlated with nodal involvement. Furthermore, squamous tumours with LOH involving 11p13 loci had significantly worse survival than those without LOH. These data suggest that tumor suppressor gene(s) on 11p affect the progression of NSCLC, particularly squamous cell carcinomas.

Entities:  

Mesh:

Year:  1994        PMID: 7522041     DOI: 10.1002/gcc.2870100306

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

1.  Nuclear RNR-α antagonizes cell proliferation by directly inhibiting ZRANB3.

Authors:  Yuan Fu; Marcus J C Long; Somsinee Wisitpitthaya; Huma Inayat; Timothy M Pierpont; Islam M Elsaid; Jordana C Bloom; Joaquin Ortega; Robert S Weiss; Yimon Aye
Journal:  Nat Chem Biol       Date:  2018-08-27       Impact factor: 15.040

Review 2.  Molecular biology of lung cancer: clinical implications.

Authors:  Jill E Larsen; John D Minna
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

3.  Recessive oncogenes: current status.

Authors:  Xiang Gao; Kenneth V Honn
Journal:  Pathol Oncol Res       Date:  1995       Impact factor: 3.201

4.  Loss of heterozygosity on chromosome 11p15 during histological progression in microdissected ductal carcinoma of the breast.

Authors:  J H Lichy; M Zavar; M M Tsai; T J O'Leary; J K Taubenberger
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

5.  A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.

Authors:  David S Shames; Luc Girard; Boning Gao; Mitsuo Sato; Cheryl M Lewis; Narayan Shivapurkar; Aixiang Jiang; Charles M Perou; Young H Kim; Jonathan R Pollack; Kwun M Fong; Chi-Leung Lam; Maria Wong; Yu Shyr; Rita Nanda; Olufunmilayo I Olopade; William Gerald; David M Euhus; Jerry W Shay; Adi F Gazdar; John D Minna
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

6.  Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features.

Authors:  J Geradts; K M Fong; P V Zimmerman; J D Minna
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

7.  New panel of microsatellite alterations detectable in the EBC for lung cancer prognosis.

Authors:  Giovanna E Carpagnano; Donato Lacedonia; Elisabetta Crisetti; Domenico Martinelli; Maria P Foschino-Barbaro
Journal:  J Cancer       Date:  2016-11-25       Impact factor: 4.207

8.  Evaluation of Potential Mechanisms Controlling the Catalase Expression in Breast Cancer Cells.

Authors:  Christophe Glorieux; Juan Marcelo Sandoval; Nicolas Dejeans; Sandrine Nonckreman; Khadija Bahloula; Hélène A Poirel; Pedro Buc Calderon
Journal:  Oxid Med Cell Longev       Date:  2018-01-28       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.